It is difficult to forecast in the long term, and even in the short term, due to the current situation. Nevertheles, there is something clear, the determination of GOCO for retaking its activity in the point it was left.
This year, the GOCO meeting that the past 2020 had to be postponed will be carried out, either in person or virtually. The location, the topics and the ponents have been preserved as much as it was possible. So, we can say that it was only a parenthesis in the collaborative path that GOCO has always been, and it increased the desire to continue and firm it up.
We are pleased to invite you to be part of our next meeting, what will for sure strenghten professional and personal ties between members, as it always did.
We hope to see you next November 26th in Badalona!!! (… or on the net)
For more info click here
Dear colleagues,
Due to the current health situation with the COVID 19 coronavirus pandemic, the GOCO Board in conjunction with the Organising Committee of the 28th GOCO Congress have decided to postpone it until next year (date to be determined). It will therefore be organised by the Radiotherapy Oncology Service of the Catalan Institute of Oncology - H. Germans Trias i Pujol
We thank all the speakers and all those who have been preparing papers, as well as the local committee, for all the work done. We are counting on you all for the next year.
On the other hand, we inform you that as stablished in the statutes, we must do an annual meeting in which, in addition, part of the board will be renewed. This meeting will take place telematically, probably on the same day scheduled for the congress. In order to make it easier, it is proposed that each service designates a representative, what would make it easier to vote for the renewal of the board. Soon, it will be sent the anouncement of the date, the candidates and the link to the meeting..
Best regards from the GOCO Board
On November 16th, the XXVI Congress of Grup Oncologic Catala-Occita took place in Hospital del Mar of Barcelona. The participation was of 207 attendees, of whom 51 were physicians, 19 physicists, 69 technicians, 6 nurses, 5 professors and 33 students from technician’s schools.
The global theme of this congress has been to discuss the possibilities of new indications in Radiotherapy in the context of new available technologies and new strategies of treatment.
So, from the clinical point of view, the possibilities of Intraoperative Radiotherapy with low energy photon were presented, focussing on lung primary, breast and disseminated non oligometastasic prostate tumours, but in reference to new systemic treatment schedules. In the global sessions, the indication of re-irradiation for prostate, breast and head and neck cancers were considered, as well as the radiotherapy role in the handle of benign proliferative or inflammatory diseases with no response to standard treatments.
From the technological side, tracking systems of prostate with transponders detection and verification systems based on surfaces superposition experiences were shared to be used as a quality control for patient positioning.
In the medical physicist sessions, dual energy tomography, 3D printers uses in radiotherapy for cast and molds experiences were presented. Also the Scripting task group of the Societat Catalana de Física Mèdica explained the uses and possibilities of scripts.
In parallel, the technician sessions were focussed in extreme hypofractionating and the practical side of its application in stereotactic cranial and extracranial anatomical locations.
The level of the more than 40 conferences, presentations and communications exposed was very high, contributing to the satisfaction expressed by the attendees at the end of this edition devoted to boost the expansion of the new indications of radiotherapy to our environment within the pale of our group GOCO.
Thank you very much to all the participants!
"REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY" is publishing soon a Special Volume about Liver SBRT. It is edited by Drs M.Macià and C. Llacer-Moscardó.
We share the volume Index, where you can see the different articles, where great specialists in the matter have participated.
Special Issue: 21 Liver SBRT
Under the 4th International Workshop on the treatment of liver and lung metastases in colorectal cancer, organized by the Hospital Universitari Mutua Terrassa, University of Barcelona, has occurred Panitumumab symposium: the value of personalized medicine Amgen and in which participated Dr. Eduardo Diaz-Rubio, head of Medical Oncology University Hospital Clinico San Carlos, Madrid, Dr. Jean-Yves Douillard, the Institut de l'ouest Cancérologie (ICO) René Gauducheu, Nantes, France and Dr. Cristina Nadal Hospital Clínic of Barcelona. During the symposium the results of the PRIME study published in the New England Journal of Medicine on biomarker RAS mutational status, by Dr. Jean-Yves Douillard, first author of the paper were presented. According Douillard, the study shows that "in a patient with metastatic colorectal cancer, the probability that the biomarker is mutated RAS is 50-50".
Page 1 of 2